Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC

This study is collecting tumor and blood samples from people with triple-negative breast cancer (TNBC) before, during, and after treatment to understand why some cancers come back and to develop better tests for predicting and preventing recurrence. This is a biobank and precision medicine study, not a treatment comparison. **You may be eligible if...** - You are 18 or older with Stage I–III triple-negative or HER2-negative/hormone receptor-low breast cancer confirmed by biopsy - You are scheduled to receive standard treatment (chemotherapy, surgery, or both) - You are willing to provide tissue and blood samples at multiple timepoints **You may NOT be eligible if...** - You have Stage IV (metastatic) breast cancer - You are unable to provide tissue samples - You have a serious co-existing medical condition Talk to your doctor to see if this trial is right for you.